Literature DB >> 24129425

[ANCA-associated vasculitis and malignancy : current evidence for cause and consequence relationships].

M Zänker1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24129425     DOI： 10.1007/s00393-013-1283-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  6 in total

Review 1.  Diagnosis and management of ANCA associated vasculitis.

Authors:  Annelies Berden; Arda Göçeroglu; David Jayne; Raashid Luqmani; Niels Rasmussen; Jan Anthonie Bruijn; Ingeborg Bajema
Journal:  BMJ       Date:  2012-01-16

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Authors:  Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2012-11

Review 4.  Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.

Authors:  C Heijl; L Harper; O Flossmann; I Stücker; D G I Scott; R A Watts; P Höglund; K Westman; A Mahr
Journal:  Ann Rheum Dis       Date:  2011-05-25       Impact factor: 19.103

5.  Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.

Authors:  Mikkel Faurschou; Inge Juul Sorensen; Lene Mellemkjaer; Anne Gitte Rasmussen Loft; Bjarne Svalgaard Thomsen; Niels Tvede; Bo Baslund
Journal:  J Rheumatol       Date:  2007-10-15       Impact factor: 4.666

6.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane
Journal:  Ann Rheum Dis       Date:  2012-11-07       Impact factor: 19.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.